Amphivena Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Amphivena Therapeutics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage T-cell engager platform with differentiated MDSC-targeting mechanism addressing immunotherapy resistance, but execution risk remains material given clinical-stage status and limited recent transparency. Amphivena demonstrates a validated technology platform with clinical proof-of-concept (Phase 1 data showing complete response), significant institutional backing ($88.5M raised), and a strategic focus on immuno-oncology—a.
What is Amphivena Therapeutics, Inc.'s industry? Amphivena Therapeutics, Inc. (amphivena.com) operates in Oncology Drugs. AskCyborg classifies Amphivena Therapeutics, Inc. under Oncology Drugs in its company registry.
Amphivena Therapeutics, Inc. is a privately held, clinical-stage, oncology company based in South San Francisco, CA with a mission to restore anti-cancer immunity in patients and to take cancer treatment beyond the li...
Cyborg Score thesis
Early-stage T-cell engager platform with differentiated MDSC-targeting mechanism addressing immunotherapy resistance, but...
Read the full analyst-debate transcript →Get the Latest Amphivena Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAmphivena Therapeutics, Inc. Overview
Pro stress-test →Amphivena Therapeutics, Inc. is a privately held, clinical-stage, oncology company based in South San Francisco, CA with a mission to restore anti-cancer immunity in patients and to take cancer treatment beyond the limits of immunotherapy. The company's proprietary Amphivena ReSTORE platform of bivalent T-cell engagers is designed to selectively relieve immune suppression and drive T-cell activation/polarization in patients.
Strategic Profile
Pro stress-test →The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy, and in parallel, drives improved T cell effector function. The company is advancing AMV564 through Phase 1 clinical development across multiple solid tumor indications and hematologic malignancies.
Competitive Landscape
Pro stress-test →Amphivena competes in the immuno-oncology and T-cell engager space against established players developing checkpoint inhibitors and bispecific T-cell engaging antibodies. Direct competitors include Roche/Genentech (BiTE platform), Juno Therapeutics/Bristol Myers Squibb (CAR-T), and emerging bispecific companies like Thirty Thirty Therapeutics and Alnylam. Amphivena's differentiation lies in its MDSC-targeting, bivalent T-cell engager approach combined with subcutaneous dosing, positioning it as an adjunct to rather than replacement for checkpoint inhibitors.
Industry Context
Amphivena Therapeutics, Inc. operates in Oncology Drugs.
Key facts
Founded: 2012 · Headquarters: South San Francisco, US · Employees: 17